Dutasteride for reducing the risk of developing prostate cancer in men who are considered to be at increased risk of developing the disease
Status Suspended
Process STA pre-2018
Referral date 01 March 2009
Topic area
  • Cancer
  • Urogenital

Cancer reform strategy Batch 3

Provisional Schedule

Closing date for invited submissions / evidence submission: 18 January 2011
1st appraisal committee meeting: 01 January 2100

Project Team

Communications manager: Alice Law
Executive Lead: Peter Littlejohns
Project manager: Lori Farrar
Technical Lead: Panagiota Vrouchou


Manufacturers/sponsors GlaxoSmithKline (dutasteride)
Others Department of Health
  Hywel Dda Local Health Board
  Welsh Assembly Government
Patient/carer groups Prostate Cancer Charity
Professional groups British Uro-Oncology Group
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  United Kingdom Oncology Nursing Society


Associated Guideline Groups None
Associated Public Health Groups None
Comparator manufacturers None
Evidence Review Group National Institute for Health Research Health Technology Assessment Programme
  Southampton Health Technology Assessment Centre
General Commissioning Support Appraisals Service
  Department of Health,Social Services and Public Safety for Northern Ireland
  NHS Quality Improvement Scotland
Relevant research groups MRC Clinical Trials Unit
  Prostate Action


Key events during the development of the guidance:

Date Update
27 April 2011

NICE has been informed by the manufacturer of dutasteride, GSK, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 14 September 2011 has been cancelled.

NICE will continue to monitor any development and update this webpage if the situation changes.

21 January 2011

NICE has re-scheduled the first Appraisal Committee meeting for a number of technology appraisal topics.

In rescheduling these topics we have been careful to maintain our ability to issue timely recommendations.

This appraisal of Dutasteride for reducing the risk of developing prostate cancer is one of the topics that has been identified.

The first appraisal committee discussion will now take place on 14 September 2011. The second committee meeting (if required) will also be rescheduled.

30 July 2010

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin end of October 2010. The deadline for submissions is expectedin approximately mid January 2011.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance